Epothilone B in Treating Patients With CNS Metastases From Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

May 31, 2012

Conditions
Breast CancerMetastatic Cancer
Interventions
BIOLOGICAL

epothilone B

Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

02114

Massachusetts General Hospital, Boston

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

David Peereboom, MD

OTHER

NCT00450866 - Epothilone B in Treating Patients With CNS Metastases From Breast Cancer | Biotech Hunter | Biotech Hunter